Literature DB >> 1570348

Ovarian expression of cellular Ki-ras p21 varies with physiological status.

S Palejwala1, L T Goldsmith.   

Abstract

To elucidate the potential role of the ras protooncogene proteins in a specific tissue, the present study determined the levels of individual c-ras-encoded p21 proteins in the rat ovary during various stages of physiological function. p21 protein was extracted from ovaries taken from immature normal female rats, mature nonpregnant animals in the metestrus stage of the estrus cycle, rats at various stages of pregnancy, and actively lactating animals. Levels of individual p21s were evaluated by immunoblot analysis with specific antibodies to the p21 proteins encoded by the Kirsten, Harvey, and neuroblastoma c-ras protooncogenes, c-Ki-ras, c-Ha-ras, and N-ras. Results showed that c-Ki-ras p21 is at its lowest level in the immature ovary and increases with development of the corpora lutea to its highest levels at day 16 of pregnancy, after which levels decline and then rise again during lactation. This pattern, which mimics that of circulating progesterone levels, suggests that ovarian c-Ki-ras p21 levels are regulated and that c-Ki-ras p21 plays a role in the differentiated function of the rat ovary, likely the luteal compartment. In contrast, levels of c-N-ras p21 did not appear to vary with changes in the physiological function of the ovary but appeared to be constitutive. A preferential role for the c-Ki-ras p21 may be due to the documented unique differences in the structure of the carboxyl terminus of this particular c-ras p21.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570348      PMCID: PMC525661          DOI: 10.1073/pnas.89.9.4202

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Expression of the H-ras proto-oncogene is controlled by alternative splicing.

Authors:  J B Cohen; S D Broz; A D Levinson
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

2.  Detection of Ki-ras proto-oncogene protein by a specific monoclonal antibody.

Authors:  S Palejawala; L T Goldsmith
Journal:  Biotechniques       Date:  1991-11       Impact factor: 1.993

Review 3.  Cooperation between oncogenes.

Authors:  T Hunter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Evidence for luteal cell hyperplasia during pregnancy.

Authors:  L T Goldsmith; A N Hirshfield
Journal:  Biol Reprod       Date:  1991-03       Impact factor: 4.285

6.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

7.  All ras proteins are polyisoprenylated but only some are palmitoylated.

Authors:  J F Hancock; A I Magee; J E Childs; C J Marshall
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

8.  Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy.

Authors:  P G Chesa; W J Rettig; M R Melamed; L J Old; H L Niman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

9.  p21ras is modified by a farnesyl isoprenoid.

Authors:  P J Casey; P A Solski; C J Der; J E Buss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Contrasting expression patterns of three members of the myc family of protooncogenes in the developing and adult mouse kidney.

Authors:  G Mugrauer; P Ekblom
Journal:  J Cell Biol       Date:  1991-01       Impact factor: 10.539

View more
  8 in total

1.  Changes in intracellular calpastatin localization are mediated by reversible phosphorylation.

Authors:  M Averna; R de Tullio; M Passalacqua; F Salamino; S Pontremoli; E Melloni
Journal:  Biochem J       Date:  2001-02-15       Impact factor: 3.857

2.  Immunohistochemical Expression of N-ras Oncogene is a Late Event in Head and Neck Carcinomas.

Authors:  John S McDonald; Keith M Wilson; Peter Gartside; Robert L Sonke; Ljiljana Pavelic; Eric Okum; Julie Neanen; Jack L Gluckman; Zlatko P Pavelic
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

3.  Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.

Authors:  H J Andreyev; P J Ross; D Cunningham; P A Clarke
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis.

Authors:  Roberto Stifanese; Monica Averna; Roberta De Tullio; Marco Pedrazzi; Francesco Beccaria; Franca Salamino; Marco Milanese; Giambattista Bonanno; Sandro Pontremoli; Edon Melloni
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

5.  Functional role of HSP90 complexes with endothelial nitric-oxide synthase (eNOS) and calpain on nitric oxide generation in endothelial cells.

Authors:  Monica Averna; Roberto Stifanese; Roberta De Tullio; Mario Passalacqua; Franca Salamino; Sandro Pontremoli; Edon Melloni
Journal:  J Biol Chem       Date:  2008-08-05       Impact factor: 5.157

6.  Protein kinase C-theta is specifically localized on centrosomes and kinetochores in mitotic cells.

Authors:  M Passalacqua; M Patrone; B Sparatore; E Melloni; S Pontremoli
Journal:  Biochem J       Date:  1999-01-01       Impact factor: 3.857

7.  Changes in calcium influx affect the differentiation of murine erythroleukaemia cells.

Authors:  B Sparatore; A Pessino; M Patrone; M Passalacqua; E Melloni; S Pontremoli
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

8.  Calpain inhibition promotes the rescue of F(508)del-CFTR in PBMC from cystic fibrosis patients.

Authors:  Monica Averna; Marco Pedrazzi; Laura Minicucci; Roberta De Tullio; Federico Cresta; Franca Salamino; Sandro Pontremoli; Edon Melloni
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.